Akzo Nobel N.V. — M&A Activity 2007

Nov 19, 2007

Akzo Nobel completes OBS sale

Amsterdam, the Netherlands, November 19, 2007 – Akzo Nobel N.V. has today completed the sale of Organon BioSciences N.V. to Schering-Plough Corporation for EUR 11 billion.

Confirmation of the completion of the transaction comes after Schering-Plough received all the necessary approvals, including clearance from the U.S. Federal Trade Commission and the European Commission.

"It is with mixed emotions that we say goodbye to these businesses, which have been part of Akzo Nobel for so many years, said CEO Hans Wijers. "I would like to thank all the OBS employees for their contributions. I am convinced that Schering-Plough will prove to be a stimulating new owner, allowing the Pharma activities to flourish and grow. I wish all the people at OBS a successful future."

Schering-Plough's global headquarters will continue to be based in Kenilworth, NJ, in the United States, while Boxmeer in the Netherlands will become the HQ for its worldwide animal health business.

First announced in March, the divestment of Akzo Nobel's pharmaceutical activities means that the company can now concentrate its strategic focus on becoming a world-leading industrial company exclusively dedicated to coatings and specialty chemicals.

---

Note to editors

Akzo Nobel is a Fortune Global 500 company and is listed on Euronext Amsterdam. It is also the Chemicals Industry leader on the Dow Jones Sustainability Indexes and Akzo Nobel is included on the FTSE4Good Index. Based in the Netherlands, we are a multicultural organization serving customers throughout the world with coatings, chemicals and human and animal healthcare products. We employ around 62,000 people and conduct our activities in these four segments, with operating subsidiaries in more than 80 countries. Consolidated revenues for 2006 totaled EUR 13.7 billion. The financial results for the year 2007 will be published on March 6, 2008.

Internet: www.akzonobel.com

Not for publication – for more information Akzo Nobel N.V. Corporate Media Relations, tel. +31 20 502 7833 Contact: Marc Michelsen

Akzo Nobel nv Strawinskylaan 2555 P.O. Box 75730 1070 AS Amsterdam The Netherlands Tel.: +31 20 502 7833 Fax: +31 20 502 7604

Safe Harbor Statement*

This press release contains statements which address such key issues as Akzo Nobel's growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, progress of drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more comprehensive discussion of the risk factors affecting our business please see our Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the company's corporate website www.akzonobel.com.

* Pursuant to the U.S. Private Securities Litigation Reform Act 1995.